BioSpace News Archive

Danaher will deliver 5.5784 shares of Envista common stock to or at the direction of any such tendering stockholder.

In addition, the Company has granted the Purchasers and certain finders an aggregate of 2,693,573 three-year warrants to purchase up to an additional 2,693,573 ordinary shares at an exercise price between $2.37 and $2.96 per share

Shopko Optical continues to provide top-quality eye care with the support of Monarch Alternative Capital

SQI is a Toronto-based life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced multiplexed diagnostics.

GenEdit has developed a comprehensive delivery system for CRISPR-based therapeutics, including gene knockout and gene repair therapies, to enable safer delivery options with improved efficiency.

Vanguard will be able to enhance their offerings to enable clients the capability to meet the domestic and international regulatory requirements of the cannabinoid industry.

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced positive pivotal data from the HER2CLIMB trial evaluating tucatinib in patients with HER2-positive metastatic breast cancer (MBC) were presented at the 2019 San Antonio Breast Cancer Symposium (SABCS) and simultaneously published in the New England Journal of Medicine (NEJM).

The 2020 Entrepreneur and Investor Summit, along with Title Sponsor, Simpson Thacher, will host the year’s premier gathering of Utah’s life sciences’ innovators and investors, featuring notable speakers, education sessions, and valuable networking opportunities.

It is expected that data from GBM AGILE will be used to seek marketing approval for GDC-0084 from FDA and other regulatory agencies.

Biologics License Application (BLA) submission to FDA expected before the end of 2019